Other research analysts also recently issued research reports about the stock. Deutsche Bank upped their price objective on shares of Blueprint Medicines from $85.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Zacks Investment Research downgraded shares of Blueprint Medicines from a “buy” rating to a “hold” rating and set a $68.00 price target on the stock. in a research note on Friday, May 22nd. Barclays reissued a “neutral” rating on shares of Blueprint Medicines in a research report on Wednesday, July 15th. Robert W. Baird raised their price objective on Blueprint Medicines from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Tuesday, July 14th. Finally, HC Wainwright lifted their price objective on Blueprint Medicines from $66.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $96.15.
BPMC stock opened at $73.18 on Friday. The company has a 50 day moving average price of $76.68 and a two-hundred day moving average price of $67.22. The company has a debt-to-equity ratio of 0.13, a quick ratio of 7.14 and a current ratio of 7.17. The stock has a market capitalization of $3.97 billion, a P/E ratio of -9.54 and a beta of 1.09. Blueprint Medicines has a one year low of $43.29 and a one year high of $101.76.
In other Blueprint Medicines news, insider Ariel Hurley sold 700 shares of Blueprint Medicines stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $75.00, for a total value of $52,500.00. Following the completion of the transaction, the insider now directly owns 10,684 shares in the company, valued at $801,300. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Nicholas Lydon sold 26,007 shares of the company’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $80.45, for a total value of $2,092,263.15. Following the transaction, the director now directly owns 48,340 shares of the company’s stock, valued at $3,888,953. The disclosure for this sale can be found here. In the last ninety days, insiders sold 66,349 shares of company stock valued at $5,001,908. 3.81% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently modified their holdings of the stock. Bourgeon Capital Management LLC bought a new stake in Blueprint Medicines in the first quarter valued at $29,000. Advisor Group Holdings Inc. bought a new position in shares of Blueprint Medicines during the first quarter worth about $32,000. Exane Derivatives increased its holdings in shares of Blueprint Medicines by 35,300.0% in the 1st quarter. Exane Derivatives now owns 1,770 shares of the biotechnology company’s stock worth $104,000 after acquiring an additional 1,765 shares during the period. Cutler Group LP lifted its position in Blueprint Medicines by 480.0% in the 1st quarter. Cutler Group LP now owns 1,900 shares of the biotechnology company’s stock valued at $111,000 after purchasing an additional 2,400 shares during the last quarter. Finally, Stifel Financial Corp acquired a new position in Blueprint Medicines during the 4th quarter valued at about $275,000. Hedge funds and other institutional investors own 97.96% of the company’s stock.
About Blueprint Medicines
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Featured Article: What does an outperform rating mean?
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.